These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 2958397

  • 1. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
    Possinger K, Wagner H, Langecker P, Schmid L, Willich S, Wilmanns W.
    Fortschr Med; 1987 Jul 30; 105(22):421-4. PubMed ID: 2958397
    [No Abstract] [Full Text] [Related]

  • 2. [Value of hormone therapy in metastasizing breast cancer].
    Samonigg H.
    Wien Med Wochenschr; 1985 Dec 31; 135(23-24):602-7. PubMed ID: 2937208
    [Abstract] [Full Text] [Related]

  • 3. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y, Tashiro H, Hisamatsu K, Shinozuka K.
    Anticancer Res; 1988 Dec 31; 8(4):647-51. PubMed ID: 2972248
    [Abstract] [Full Text] [Related]

  • 4. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system].
    Schenk H, Fereberger W.
    MMW Munch Med Wochenschr; 1983 Oct 07; 125(40):875-6. PubMed ID: 6226871
    [No Abstract] [Full Text] [Related]

  • 5. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer].
    Dryzhak VI.
    Vopr Onkol; 1989 Oct 07; 35(7):771-8. PubMed ID: 2528239
    [No Abstract] [Full Text] [Related]

  • 6. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A, Tucci E, D'Aniello C, Carli A, Mariani L, De Stefano A, Nardi P.
    Chemioterapia; 1984 Oct 07; 3(5):320-3. PubMed ID: 6241848
    [Abstract] [Full Text] [Related]

  • 7. Hormone therapy in advanced breast cancer: high dose medroxyprogesterone acetate (MAP) vs tamoxifen (TMX). Preliminary results.
    Pannuti F, Martoni A, Fruet F, Strocchi E, Di Marco AR.
    Eur J Cancer (1965); 1980 Oct 07; Suppl 1():93-8. PubMed ID: 6459237
    [No Abstract] [Full Text] [Related]

  • 8. [Hormonal control of disseminated breast cancer].
    Voznyĭ EK, Meshcheriakova NG, Biakhov MIu, Vasiuta NIu.
    Sov Med; 1990 Oct 07; (6):94-7. PubMed ID: 2144368
    [No Abstract] [Full Text] [Related]

  • 9. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K, Ogawa M, Horikoshi N, Inoue K, Mukaiyama T, Nakamura T, Ito Y, Imajo K, Ozeki H.
    Gan To Kagaku Ryoho; 1986 Oct 07; 13(11):3198-202. PubMed ID: 2946264
    [Abstract] [Full Text] [Related]

  • 10. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
    Brockerhoff P, Grill HJ, Holzer A, Kreienberg R, Pollow K, Schicketanz KH, Schwarz V, Rathgen GH.
    Gynakol Rundsch; 1991 Oct 07; 31(4):189-200. PubMed ID: 1839014
    [Abstract] [Full Text] [Related]

  • 11. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC, Wander HE, Nagel GA, Köbberling J, Kleeberg U.
    Onkologie; 1982 Aug 07; 5 Suppl():34-41. PubMed ID: 6290955
    [Abstract] [Full Text] [Related]

  • 12. [High-dose gestagen therapy in breast cancer].
    Beaufort F, Fereberger W.
    Wien Med Wochenschr; 1983 Apr 15; 133(7):169-73. PubMed ID: 6223450
    [Abstract] [Full Text] [Related]

  • 13. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC, Wander HE, Nagel GA, Köbberling J, Kleeberg U.
    Onkologie; 1982 Aug 15; 5 Suppl():13-6. PubMed ID: 6215599
    [Abstract] [Full Text] [Related]

  • 14. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
    Flamm J, Spona J.
    Wien Klin Wochenschr; 1987 Oct 09; 99(19):682-6. PubMed ID: 2961131
    [Abstract] [Full Text] [Related]

  • 15. [High-dose gestagen therapy with medroxyprogesterone acetate in metastasizing breast carcinoma].
    Bastert G, Michel RT.
    Med Welt; 1983 Mar 25; 34(12):378-82. PubMed ID: 6222235
    [No Abstract] [Full Text] [Related]

  • 16. [Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: a dose-response evaluation].
    Tominaga T, Izuo M, Nomura Y, Kubo K, Abe O, Enomoto K, Takatani O.
    Gan To Kagaku Ryoho; 1982 Nov 25; 9(11):1994-2004. PubMed ID: 6223590
    [Abstract] [Full Text] [Related]

  • 17. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA, Jimenez MV, Villalon AH, Agustin BM.
    Southeast Asian J Trop Med Public Health; 1985 Dec 25; 16(4):634-7. PubMed ID: 2940689
    [Abstract] [Full Text] [Related]

  • 18. Depot medroxyprogesterone and breast cancer.
    Day BJ, McCallum AB, Zambrano D, Tong DD.
    N Z Med J; 1990 Jul 11; 103(893):327-8. PubMed ID: 2142520
    [No Abstract] [Full Text] [Related]

  • 19. Therapeutic activity of medroxyprogesterone acetate in metastatic breast cancer: a correlation between estrogen receptors and various dosages.
    De Lena M, Villa S, Di Fronzo G.
    Recent Results Cancer Res; 1984 Jul 11; 91():243-7. PubMed ID: 6203147
    [No Abstract] [Full Text] [Related]

  • 20. [Medroxyprogesterone acetate (MAP) and aminoglutethimide (AG) in metastatic breast carcinoma. Preliminary report on a phase II study of the German Cancer Society's Internal Medicine Oncology Task Force].
    Wander HE, Nagel GA, Blossey HC.
    Onkologie; 1982 Aug 11; 5 Suppl():28-33. PubMed ID: 6215600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.